Current mRNA therapeutics and vaccines are designed for high and ubiquitously translation. However, for many mRNA drugs and gene therapies the expression of the therapeutic RNA in all cells is undesirable and translational control must be tailored to the target tissue. To engineer cell-type specific mRNA translation this project will use rational design and high-throughput in vivo screening of structured RNA elements. RNA modules that confer cell-type-specific or cancer-specific expression will be identified to incorporate in next-generation mRNA drug designs.

  Are you interested in a PhD at the AIBN? Click here, and start your journey today. 

mRNA, therapeutics, vaccines, vaccine development, gene therapy,


Supervisor name

Dr Seth Cheetham
Group Leader and NHMRC Career Fellow
Cheetham Group

Supervisor email